

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/561,829
		Filing Date	December 21, 2005
		First Named Inventor	Shaharyar Khan
		Group Art Unit	1633
		Examiner Name	Qian Janice Li
		Attorney Docket Number	GNC 0001
Sheet	1	of	2

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner's Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/561,829
(use as many sheets as necessary)		Filing Date	December 21, 2005
		First Named Inventor	Shaharyar Khan
		Group Art Unit	1633
		Examiner Name	Qian Janice Li
Sheet	2	of	2
		Attorney Docket Number	GNC 0001

OTHER ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		CAO, et al., "In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis," <i>J. Neuroscience</i> , 22(13): 5423-31 (2002).
		DOLGILEVICH, et al., "Transduction of TAT fusion proteins into osteoclasts and osteoblasts," <i>Biochem. Biophys. Res. Commun.</i> , 299(3): 505-9 (2002).
		EMBURY, et al., "Proteins linked to a protein transduction domain efficiently transduce pancreatic islets," <i>Diabetes</i> , 50(8): 1706-13 (2001).
		FENTON, et al., "The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line," <i>J. Immunol. Methods</i> , 212(1): 41-8 (1998).
		FORRER and JAUSSI, "High-level expression of soluble heterologous proteins in the cytoplasm of <i>Escherichia coli</i> by fusion to the bacteriophage Lambda head protein D," <i>Gene</i> , 224(1-2): 45-52 (1998).
		LI, et al., "Transduction of human catalase mediated by a HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells," <i>Free Radical Biology &amp; Medicine</i> , 31(11): 1509-19 (2001).
		STERNBERG and HOESS, "Display of peptides and proteins on the surface of bacteriophage λ," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92(5): 1609-13 (1995).
		TOBOREK, et al., "HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium," <i>J. Neurochem.</i> , 84(1): 169-79 (2003).
		TSENG, et al., "Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study," <i>Mol. Pharmacology</i> , 62(4): 864-72 (2002).
		VASQUEZ and JOHNSON, "Green fluorescent protein as a reporter of adenovirus-mediated gene transfer and expression in the hypothalamic-neurohypophyseal system," <i>Methods Mol. Biol.</i> , 183: 321-9 (2002).
		VIVÈS, et al., "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272(25): 16010-7 (1997).
		WHEELER, et al., "Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain," <i>Biochem. Biophys. Res. Commun.</i> , 301(1): 54-9 (2003).

Examiner's Signature	/Qian Janice Li/ (04/08/2010)	Date Considered
----------------------	-------------------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.